CareDx, Inc. (CDNA)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
Research Workspace
Put CDNA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 34% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 43% growth a year, above the roughly 13% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 24% in its worst 12-month stretch.
View RiskCareDx’s growth claim rests on sustaining strong recent performance despite year-over-year revenue growth slowing. Revenue grew 39% in Q3 2026, down from 52% in Q2; Q3 earnings beat consensus. CDNA trades at 54× P/E versus a 37× peer median and 51× its history. The market is pricing in more growth than our forecast, so expectations look full. A 15% next-quarter miss probability and potential guidance reversal threaten confidence in that premium. Peer multiples imply a price about 43% below where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. CDNA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 7 analysts currently covering CDNA (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for CDNA in the last 4 months.
Continue this research
Compare CDNA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CDNA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put CDNA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Grow core Testing Services and Patient and Digital Solutions
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $87.41
The last 12 months of price, then the range of analyst 12-month targets from today’s $87.41.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Higher 2026 revenue outlook supports core growth; planned AlloHeme launch adds a future growth opportunity.

Advances: Grow core Testing Services and Patient and Digital Solutions
Official earnings-call update provides material evidence on growth and execution against objectives.

Advances: Complete merger with Naveris, Inc.
Naveris deal supports growth objective.
Advances: Increase revenue guidance for 2026
Q1 growth aligns with revenue guidance.